TrialsgrambetaRCTs are beautiful

CLEOPATRA

2012

Clinical Evaluation of Pertuzumab and Trastuzumab

In 808 patients with HER2-positive metastatic breast cancer, first line, pertuzumab + trastuzumab + docetaxel improved progression-free and overall survival compared with placebo + trastuzumab + docetaxel.

Result

Efficacy: Independent-review PFS; final OSHR 0.62

Below 1 favours pertuzumab + trastuzumab + docetaxel, above 1 favours placebo + trastuzumab + docetaxel.

Event rates Pertuzumab + trastuzumab + docetaxel 18.5 vs placebo + trastuzumab + docetaxel 12.4 months

Also reported: Final OS 56.5 vs 40.8 months (HR 0.68).

Original publication
Subtopic
HER2+ metastatic
Design
Double-blind RCT
Relevance
Practice-defining: a trial the field needs to know.
Source
Baselga J, et al. N Engl J Med. 2012;366(2):109-119; Swain SM, et al. N Engl J Med. 2015;372(8):724-734.doi 10.1056/NEJMoa1113216

Discussion & critique

Established dual HER2 blockade plus taxane as first-line standard in HER2+ metastatic breast cancer. Later displaced by trastuzumab deruxtecan in the second line (DESTINY-Breast03).